Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
scientific article published on 18 September 2020
Author/s
author: Georgina V. Long, Andrey Meshcheryakov, James Larkin, Paolo Antonio Ascierto, Dirk Schadendorf, Jean-Jacques Grob, Ralf Gutzmer, Paul Lorigan, Nageatte Ibrahim, Stefan Suciu, Caroline Robert, Alexander M. M. Eggermont, Christian U Blank, Piotr Rutkowski, Matteo Carlino
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.